The last four years have brought significant CEO turnover in the drug industry. Almost every big pharma has felt the churn, including Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc., Roche AG, Sanofi SA, Eli Lilly and Co., Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., to name a few.